Intellia Therapeutics, Inc. (NTLA) Social Stream



Intellia Therapeutics, Inc. (NTLA): $61.03

-6.71 (-9.91%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NTLA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 491

in industry

Featured Post From StockTwits About NTLA

(04/29) Gene Therapy stocks down 3.2% on average(mean) in a day. median return is -0.5%. Top movers are $ADVM -62.3% $CAPR 14.9% $NTLA -6.1% $EDIT -4.0% $SGMO -3.5%. The sector return (on average) over last 4 weeks is -0.6%. 5D rolling correlation is down from the recent high of 68% to 45%.
For detail or full list visit https://marketcomposite.com/topic?name=Gene%20Therapy
marketcomposite, published April 30, 2021

What Else are NTLA Traders Talking About?


Other tickers frequently mentioned alongside NTLA are EDIT, CRSP, ADVM and CAPR.

Other Notable StockTweets About NTLA


$CRSP Next leg up next week

We broke out yesterday then 30 mins later Joe let us down....😬

Good week all the same & I can see us moving up to $135-150 soon

We are leading the way and have loads of cash !!!!! 🧬

Loads of bullish sentiment on Twitter, Bloomberg & in the general media on CRSPR this week 📈

$EDIT $NTLA $SMGO $TSLA $PLTR

BTC2021, published April 23, 2021

$CRSP $EDIT $NTLA

Recent CRSP CEO quote which is ~$250-300 stock price near term 🧬📈

“So, quite a bit happening for us from a data catalyst standpoint, but overall, I think we're very pleased with the ability to have a very talented group of people at CRISPR doing all this work, a market cap that that provides us a very strong balance sheet position. And ultimately, a set of portfolio choices which allow us to scale this company to a $20 billion, $25 billion company in the in the near-term should we get positive data”

BTC2021, published April 14, 2021

$CRSP Remember Sam (CEO) said the market cap will be $20-25bn ‘near term’ recently

We will re-rate fast and hard soon, he knows what’s coming 📈🧬

“So, quite a bit happening for us from a data catalyst standpoint, but overall, I think we're very pleased with the ability to have a very talented group of people at CRISPR doing all this work, a market cap that that provides us a very strong balance sheet position. And ultimately, a set of portfolio choices which allow us to scale this company to a $20 billion, $25 billion company in the in the near-term should we get positive”

$NTLA $EDIT

BTC2021, published April 10, 2021

$NTLA 📜 SEC Form 4: M John Leonard exercised 71,041 units of Common Stock at a strike of $14.15 and sold $3,195,661 worth of Common Stock (38,209 units at $83.64), increasing direct ownership by 5% to 693,368 units

https://quantisnow.com/insight/583449?s=s

#healthcare

Quantisnow, published April 3, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4821 seconds.